New Pain Target LanCL1 Opens Door to Better Neuropathic Pain Treatment
Lateral Pharma identifies LanCL1 as a novel target for chronic neuropathic pain, with Phase 1b data showing real pain reduction.
Summary
Researchers have identified a protein called LanCL1 as a new target for treating chronic neuropathic pain — a condition affecting roughly 10% of people worldwide. Lateral Pharma, working with teams from Monash University, the University of Bristol, and others, published findings in the journal PAIN showing that their experimental peptide drug LAT8881 works through this protein. In an early-phase clinical trial involving patients with chronic lower back nerve pain, LAT8881 was safe, well tolerated, and produced meaningful reductions in pain. This discovery not only explains how the drug works but also opens a new biological pathway that could lead to better treatments for nerve pain — a condition notoriously difficult to manage with existing medications.
Detailed Summary
Chronic neuropathic pain — caused by nerve damage or dysfunction — affects around 10% of the global population and remains one of medicine's most stubborn treatment challenges. Existing options like opioids and anticonvulsants offer limited relief and carry significant side effects, making new targets urgently needed. This discovery may represent a meaningful step forward.
Lateral Pharma, in collaboration with researchers from Monash University, the University of Warwick, the University of Bristol, Pacific Discovery Services, and Evotec, has identified Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The findings were published in PAIN, a peer-reviewed journal, lending the discovery credible scientific standing.
The company's lead compound, LAT8881, is a first-generation Stressed Cell Protectant peptide that acts through the LanCL1 pathway. This mechanistic insight is particularly valuable because it explains the biological basis of the drug's effects and validates LanCL1 as a genuine target rather than an incidental finding. Understanding the mechanism of action is critical for refining future drug candidates and anticipating off-target effects.
In a Phase 1b clinical trial in patients with chronic lumbar radicular pain — a common form of neuropathic pain radiating from the lower spine — LAT8881 demonstrated a favorable safety profile, was well tolerated, and produced clinically meaningful reductions in provoked pain. This early human data, combined with the mechanistic publication, positions the company for more advanced trials.
Beyond pain, Lateral Pharma notes that LanCL pathway activation has potential relevance to broader neurology, infectious respiratory disease, and healthy longevity. However, Phase 1b data is preliminary, and larger randomized controlled trials will be essential to confirm efficacy, optimal dosing, and long-term safety before this therapy reaches patients.
Key Findings
- LanCL1 protein identified as a novel, validated target for treating chronic neuropathic pain in peer-reviewed research.
- LAT8881 peptide drug acts through LanCL1, explaining its mechanism of action for the first time.
- Phase 1b trial showed LAT8881 was safe, well tolerated, and reduced provoked pain in lumbar radicular pain patients.
- Chronic neuropathic pain affects roughly 10% of the global population, representing a massive unmet medical need.
- LanCL pathway may have broader applications in neurology and healthy longevity beyond pain management.
Methodology
This is a news report summarizing a peer-reviewed study published in PAIN, a reputable journal in pain research. The findings are supported by both preclinical mechanistic data and a Phase 1b human clinical trial. The article originates from a company press release, so independent verification of claims against the primary publication is advisable.
Study Limitations
Phase 1b trials are small and designed primarily to assess safety, not definitive efficacy — larger Phase 2 and 3 trials are needed. The article is based on a company announcement, which may emphasize positive results. Full study data, sample size, and placebo-controlled outcomes should be reviewed in the primary PAIN publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.